A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
05 2021
Historique:
revised: 08 01 2021
received: 14 07 2020
accepted: 09 02 2021
pubmed: 2 3 2021
medline: 1 4 2022
entrez: 1 3 2021
Statut: ppublish

Résumé

Molecular diagnosis for Duchenne and Becker muscular dystrophies (DMD/BMD) involves a two-tiered approach for detection of deletions/duplications using MLPA or array CGH, followed by sequencing of coding and flanking intronic regions to detect sequence variants, which is time-consuming and expensive. We have developed a comprehensive next-generation sequencing (NGS)-based single-step assay to sequence the entire 2.2 Mb of the DMD gene to detect all copy number and sequence variants in both index males and carrier females. Assay validation was 100% concordant with other methodologies. A total of 772 samples have been tested, of which 62% (N = 480) were index cases with a clinical suspicion of DMD. Carrier testing females account for 38% (N = 292). Molecular diagnosis was confirmed in 86% (N = 413) of the index cases. Intragenic deletions and duplications (single-exon or multi-exon) were detected in 60% (N = 247) and 14% (N = 58) of the index cases, respectively. Full-sequence analysis of the entire gene allows for detection of deep intronic pathogenic variants and accurate breakpoint detection of CNVs involving similar exons, which could have an impact on the outcome of clinical trials. This comprehensive assay is highly sensitive for diagnostic testing for DMD and is also suitable for confirmatory testing for newborn screening for DMD.

Identifiants

pubmed: 33644936
doi: 10.1002/humu.24191
doi:

Substances chimiques

Dystrophin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

626-638

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Aartsma-Rus, A., Hegde, M., Ben-Omran, T., Buccella, F., Ferlini, A., Gallano, P., Howell, R. R., Leturcq, F., Martin, A. S., Potulska-Chromik, A., Saute, J. A., Schmidt, W. M., Sejersen, T., Tuffery-Giraud, S., Uyguner, Z. O., Witcomb, L. A., Yau, S., & Nelson, S. F. (2019). Evidence-based consensus and systematic review on reducing the time to diagnosis of Duchenne muscular dystrophy. Journal of Pediatrics, 204, 305-313. https://doi.org/10.1016/j.jpeds.2018.10.043
Ahn, A. H., & Kunkel, L. M. (1993). The structural and functional diversity of dystrophin. Nature Genetics, 3(4), 283-291. https://doi.org/10.1038/ng0493-283
Alame, M., Lacourt, D., Zenagui, R., Mechin, D., Danton, F., Koenig, M., & Cossee, M. (2016). Implementation of a reliable next-generation sequencing strategy for molecular diagnosis of dystrophinopathies. Journal of Molecular Diagnostics, 18(5), 731-740. https://doi.org/10.1016/j.jmoldx.2016.05.003
Alazami, A. M., Patel, N., Shamseldin, H. E., Anazi, S., Al-Dosari, M. S., Alzahrani, F., & Alkuraya, F. S. (2015). Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Reports, 10(2), 148-161. https://doi.org/10.1016/j.celrep.2014.12.015
Bakker, E., Veenema, H., Den Dunnen, J. T., van Broeckhoven, C., Grootscholten, P. M., Bonten, E. J., & Pearson, P. L. (1989). Germinal mosaicism increases the recurrence risk for 'new' Duchenne muscular dystrophy mutations. Journal of Medical Genetics, 26(9), 553-559. https://doi.org/10.1136/jmg.26.9.553
Chaubey, A., Shenoy, S., Mathur, A., Ma, Z., Valencia, C. A., Reddy Nallamilli, B. R., & Hegde, M. R. (2020). Low-pass genome sequencing: Validation and diagnostic utility from 409 clinical cases of low-pass genome sequencing for the detection of copy number variants to replace constitutional microarray. Journal of Molecular Diagnostics, 22(6), 823-840. https://doi.org/10.1016/j.jmoldx.2020.03.008
Fratter, C., Dalgleish, R., Allen, S. K., Santos, R., Abbs, S., Tuffery-Giraud, S., & Ferlini, A. (2020). EMQN best practice guidelines for genetic testing in dystrophinopathies. European Journal of Human Genetics, 28, 1141-1159. https://doi.org/10.1038/s41431-020-0643-7
del Gaudio, D., Yang, Y., Boggs, B. A., Schmitt, E. S., Lee, J. A., Sahoo, T., Eng, C. M. (2008). Molecular diagnosis of Duchenne/Becker muscular dystrophy: Enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization. Human Mutation, 29(9), 1100-1107. https://doi.org/10.1002/humu.20841
Hegde, M. R., Chin, E. L., Mulle, J. G., Okou, D. T., Warren, S. T., & Zwick, M. E. (2008). Microarray-based mutation detection in the dystrophin gene. Human Mutation, 29(9), 1091-1099. https://doi.org/10.1002/humu.20831
Lim, B. C., Lee, S., Shin, J. Y., Kim, J. I., Hwang, H., Kim, K. J., & Chae, J. H. (2011). Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: Comprehensive mutational search in a single platform. Journal of Medical Genetics, 48(11), 731-736. https://doi.org/10.1136/jmedgenet-2011-100133
Magri, F., Govoni, A., D'Angelo, M. G., Del Bo, R., Ghezzi, S., Sandra, G., & Comi, G. P. (2011). Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. Journal of Neurology, 258(9), 1610-1623. https://doi.org/10.1007/s00415-011-5979-z
Mah, J. K. (2016). Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatric Disease and Treatment, 12, 1795-1807. https://doi.org/10.2147/NDT.S93873
Mah, J. K., Selby, K., Campbell, C., Nadeau, A., Tarnopolsky, M., McCormick, A., & Yoon, G. (2011). A population-based study of dystrophin mutations in Canada. Canadian Journal of Neurological Sciences, 38(3), 465-474. https://doi.org/10.1017/s0317167100011896
Mehler, M. F. (2000). Brain dystrophin, neurogenetics and mental retardation. Brain Research: Brain Research Reviews, 32(1), 277-307. https://doi.org/10.1016/s0165-0173(99)00090-9
Mitsuhashi, S., Boyden, S. E., Estrella, E. A., Jones, T. I., Rahimov, F., Yu, T. W., & Kang, P. B. (2013). Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2. Neuromuscular Disorders, 23(12), 975-980. https://doi.org/10.1016/j.nmd.2013.08.009
Nallamilli, B. R., Ankala, A., & Hegde, M. (2014). Molecular diagnosis of Duchenne muscular dystrophy. Current Protocols in Human Genetics, 83(9.25), 21-29. https://doi.org/10.1002/0471142905.hg0925s83
Neri, M., Rossi, R., Trabanelli, C., Mauro, A., Selvatici, R., Falzarano, M. S., & Ferlini, A. (2020). The genetic landscape of dystrophin mutations in Italy: A nationwide study. Frontiers in Genetics, 11, 131. https://doi.org/10.3389/fgene.2020.00131
Okubo, M., Minami, N., Goto, K., Goto, Y., Noguchi, S., Mitsuhashi, S., & Nishino, I. (2016). Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: Validation analysis of DMD mutations. Journal of Human Genetics, 61(6), 483-489. https://doi.org/10.1038/jhg.2016.7
Piko, H., Vancso, V., Nagy, B., Ban, Z., Herczegfalvi, A., & Karcagi, V. (2009). Dystrophin gene analysis in Hungarian Duchenne/Becker muscular dystrophy families - Detection of carrier status in symptomatic and asymptomatic female relatives. Neuromuscular Disorders, 19(2), 108-112. https://doi.org/10.1016/j.nmd.2008.10.011
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., & Committee, A. L. Q. A. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405-424. https://doi.org/10.1038/gim.2015.30
Strehle, E. M., & Straub, V. (2015). Recent advances in the management of Duchenne muscular dystrophy. Archives of Disease in Childhood, 100(12), 1173-1177. https://doi.org/10.1136/archdischild-2014-307962
Tuffery-Giraud, S., Saquet, C., Chambert, S., & Claustres, M. (2003). Pseudoexon activation in the DMD gene as a novel mechanism for Becker muscular dystrophy. Human Mutation, 21(6), 608-614. https://doi.org/10.1002/humu.10214
Wang, Y., Yang, Y., Liu, J., Chen, X. C., Liu, X., Wang, C. Z., & He, X. Y. (2014). Whole dystrophin gene analysis by next-generation sequencing: A comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. Molecular Genetics and Genomics, 289(5), 1013-1021. https://doi.org/10.1007/s00438-014-0847-z
White, S. J., Aartsma-Rus, A., Flanigan, K. M., Weiss, R. B., Kneppers, A. L., Lalic, T., & den Dunnen, J. T. (2006). Duplications in the DMD gene. Human Mutation, 27(9), 938-945. https://doi.org/10.1002/humu.20367
Xie, S., Lan, Z., Qu, N., Wei, X., Yu, P., Zhu, Q., & Yi, X. (2012). Detection of truncated dystrophin lacking the C-terminal domain in a Chinese pedigree by next-generation sequencing. Gene, 499(1), 139-142. https://doi.org/10.1016/j.gene.2012.03.029
Zaum, A. K., Stuve, B., Gehrig, A., Kolbel, H., Schara, U., Kress, W., & Rost, S. (2017). Deep intronic variants introduce DMD pseudoexon in patient with muscular dystrophy. Neuromuscular Disorders, 27(7), 631-634. https://doi.org/10.1016/j.nmd.2017.04.003

Auteurs

Babi R R Nallamilli (BRR)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Alka Chaubey (A)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

C A Valencia (CA)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Leah Stansberry (L)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Andrea M Behlmann (AM)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Zeqiang Ma (Z)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Abhinav Mathur (A)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Suresh Shenoy (S)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Vidya Ganapathy (V)

Mercer University, Atlanta, Georgia, USA.

Lakshmanan Jagannathan (L)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Vinish Ramachander (V)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Alessandra Ferlini (A)

Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Lora Bean (L)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Madhuri Hegde (M)

PerkinElmer Genomics, PerkinElmer Inc, Waltham, Massachusetts, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH